Company intelligence / Profile preview
Sentinel Oncology
Cambridge, Cambridgeshire, United Kingdomsentineloncology.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has multiple preclinical programs with one program (PEP-07) in Phase 1 for Refractory Acute Myeloid Leukemia. They have licensed programs to partners including a Chk1 inhibitor to PharmaEngine and another program to Seattle Genetics.
- Therapeutic areas
- OncologyNeurologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
PharmaEngineSeattle GeneticsPhoreMost
Beyond the preview
Go deeper on Sentinel Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sentinel Oncology.